Confronting the 'Danger' of Blocking Progress on Clinical Trial Transparency

Confronting the 'Danger' of Blocking Progress on Clinical Trial Transparency

Ethical Medicines Industry Group and Sense About Science - a co-founder of the ALLTrials campaign - have written a joint letter, in support of the Health Research Authority's work to bring about greater transparency in clinical trials to the industry.

In a statement, the two bodies say the recent judicial review against the Health Research Authority (HRA), the UK’s ethical approval body for clinical trials, in which a clinical trials company tried to challenge the HRA’s attempts to monitor whether applicants are registering all their trials, has shown "that there are people who want to reverse its recent attempts to do so."

"There is a danger that politicians and others will see this backward-looking view as significant and representative of industry. It isn’t."

Monitoring compliance is one of the biggest challenges of trials transparency. The HRA had found a sensible, practical way to integrate some basic monitoring into the ethical approval process that they’re responsible for. Regulatory bodies in other countries have been considering whether it is a way forward.

In this open letter to the HRA, AllTrials and the Ethical Medicines Industry Group make it clear that AllTrials supporters, the UK biopharmaceutical industry and the English courts have all agreed that it is.

It demonstrates that forward-looking members of the industry do not want to be associated with destructive opposition to such measures to safeguard patients. EMIG director Mark Edwards says, “This highlights the critical importance of diverse organisations, like ours, working together in a balanced manner to progress key issues affecting human health”.


    You may also like...